Biogen Inc.
$252.08
+8.03 · +3.29% today
Market open · updated 12:45:29 PM ET
- High
- $255.26 9:55 AM
- Low
- $243.34 4:25 AM
Against the S&P 500 Price change through Oct 28, 2026
BIIB+38.67%
S&P 500+13.26%
BIIB+63.65%
S&P 500+12.41%
BIIB+4.06%
S&P 500+88.06%
BIIB−7.86%
S&P 500+68.51%
Key numbers
- Previous close
- $244.05
- Open
- $247.92
- Day's range
- $246.48 – $255.55
- 52-week range
- $138.00 – $258.78
- Volume
- 370,905
- Average volume
- 1.2 million
- Market value
- $37.2 billion
- Price to earnings
- 1.6last 12 months
- Earnings per share
- $2.36last 12 months
- Beta
- 0.17moves less than the market
- Dividend
- None
- 50-day average
- $225.73
- 200-day average
- $200.40
Analyst price targets and the full financials are in the terminal.
Who Biogen buys from and competes with From our value chain
Biogen in the news
- HeadlineThese Analysts Increase Their Forecasts On Biogen After Upbeat Q3 ResultsBenzinga · October 29, 2026 at 7:38 AM ET
- HeadlineBiogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026GlobeNewsWire · October 29, 2026 at 6:59 AM ET
- HeadlineBiogen Q3 Earnings Call HighlightsMarketBeat · October 28, 2026 at 6:05 PM ET
- HeadlineBiogen Inc. (BIIB) Q3 2026 Earnings Call TranscriptSeeking Alpha · October 28, 2026 at 4:00 PM ET
- HeadlineBIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View TightenedZacks Investment Research · October 28, 2026 at 2:15 PM ET
- HeadlineBig Day for Econ Data, Hyperscaler EarningsZacks Investment Research · October 28, 2026 at 11:41 AM ET
- HeadlineBiogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research · October 28, 2026 at 10:31 AM ET
- HeadlineBiogen Inc. (BIIB) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research · October 28, 2026 at 8:51 AM ET
Congress trades in BIIB
5 purchases and 3 sales in the latest 8 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Ro KhannaHouse · D-California | Sale | $1,001 - $15,000 | Sep 11, 2026 | Oct 9, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Sep 4, 2026 | Oct 9, 2026 |
| Kevin HernHouse · R-Oklahoma | Sale | $1,001 - $15,000 | Aug 18, 2026 | Sep 2, 2026 |
| Gilbert CisnerosHouse · D-California | Purchase | $1,001 - $15,000 | Jun 5, 2026 | Jul 3, 2026 |
| Gilbert CisnerosHouse · D-California | Purchase | $1,001 - $15,000 | Jan 30, 2026 | Feb 16, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Aug 26, 2025 | Sep 12, 2025 |
| Rob BresnahanHouse | Purchase | $1,001 - $15,000 | May 15, 2025 | Jun 10, 2025 |
| Rob BresnahanHouse | Sale | $1,001 - $15,000 | Apr 8, 2025 | May 8, 2025 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Biogen
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 7,500
- Headquarters
- Cambridge, Massachusetts
- Website
- biogen.com
- Listed
- Sep 17, 1991
More drug manufacturers - general stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.